Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520rizatriptan

# Rizatriptan ## Overview Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist used for the acute treatment of migraine headaches with or without aura. It possesses faster absorption kinetic properties compared to some other triptans, particularly in its orally disintegrating tablet (ODT) formulation. ## Primary Indications Acute treatment of migraine attacks in adults and pediatric patients (aged 6 to 17 years). ## Adult Dosing * **Initial Dose:** 5 mg or 10 mg. * **Redosing:** If headache recurs after initial relief, a second dose may be taken at least 2 hours after the first dose. * **Maximum Dose:** Do not exceed 30 mg in a 24-hour period. * **ODT Formulation:** If using the orally disintegrating tablet, the tablet should be placed on the tongue and allowed to dissolve; no liquid is required. ## Pediatric Dosing (6 to 17 years) Dosing is weight-based: * **Weight < 40 kg:** 5 mg. * **Weight ≥ 40 kg:** 10 mg. * **Maximum:** One dose per 24-hour period. Safety of a second dose has not been established in pediatric patients. ## Dose Adjustments * **Hepatic/Renal Impairment:** No specific adjustment is mandated by broad guidelines, but caution is advised in severe hepatic impairment. * **Propranolol Use:** Patients taking propranolol should use the 5 mg dose. The maximum dose for these patients is 15 mg in 24 hours (due to increased rizatriptan plasma concentrations). ## Contraindications * History of ischemic heart disease, coronary artery vasospasm (Prinzmetal’s angina), or myocardial infarction. * Patients with signs or symptoms of ischemic heart disease. * Uncontrolled hypertension. * History of stroke or transient ischemic attack (TIA). * Peripheral vascular disease. * Ischemic bowel disease. * Administration within 24 hours of another 5-HT1 agonist or ergotamine-type medication. * Concomitant use within 2 weeks of monoamine oxidase (MAO) inhibitors. ## Adverse Effects * **Common:** Paresthesia, dizziness, somnolence, fatigue, and sensations of tightness/pressure in the chest or throat (usually non-cardiac). * **Rare but Serious:** Myocardial infarction, arrhythmias, stroke, serotonin syndrome (especially when combined with SSRIs/SNRIs), and medication-overuse headache. ## Key Drug Interactions * **MAOIs:** Contraindicated; risk of significant increase in rizatriptan levels. * **Propranolol:** Increases rizatriptan AUC by ~70%; requires dose reduction. * **SSRIs/SNRIs:** Potential risk of serotonin syndrome; monitor for symptoms (agitation, tachycardia, hyperreflexia). * **Ergot derivatives:** Do not administer within 24 hours of each other to avoid additive vasospastic effects. ## Monitoring * Assess for cardiovascular symptoms (chest pain, shortness of breath) during the first administration. * Monitor for signs of serotonin syndrome if combined with serotonergic antidepressants. * Evaluate frequency of use to prevent medication-overuse headache (limit use to ≤10 days per month). ## Clinical Pearls * **Efficacy:** Effectiveness is best if administered as soon as possible after the onset of the migraine headache. * **Administration:** The ODT formulation does not require water, making it convenient for patients with migraine-associated nausea. * **Consistency:** If the first dose does not provide relief, patients should not take a second dose for the same attack unless instructed, but should consult their provider to reconsider the therapy. *** *Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Dosing and clinical protocols may vary by institution. Always consult the current FDA-approved package insert or a reliable electronic drug database prior to prescribing or administering medication.*